Effect of ACP-501 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Subjects With Coronary Artery Disease
An Intravenous, Open-label, Single-dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of rhLCAT in Subjects With Coronary Artery Disease
  • Phase

    Phase 1
  • Study Type

  • Status

    Completed No Results Posted
  • Intervention/Treatment

    acp-501 ...
  • Study Participants

This study is a phase 1, intravenous, open-label, single-dose escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ACP-501 (recombinant human Lecithin Cholesterol Acyl Transferase (rhLCAT)) in subjects with coronary artery disease (CAD). Four cohorts consisting of 4 subjects each will receive one dose of ACP-501. The dose will be escalated by cohort.
After signing informed consent, subjects entered into the trial will be followed for up to 8 weeks which includes: up to 4 weeks screening, entry criteria assessments on Day 0 and single-dose IV infusion on Day 1, and 4 weeks of follow-up.
Study Started
Mar 31
Primary Completion
Sep 30
Study Completion
Sep 30
Last Update
Mar 14

Drug ACP-501

A single dose infusion

ACP-501 Experimental


Inclusion Criteria:

A history of stable documented CAD

Currently non-smoking males and females ages 30 to 85 years inclusive.

o Female subjects of child-bearing potential (neither pregnant nor breast-feeding) must be using adequate birth control during study conduct.

Chronic concomitant medications must be stable for at least 2 months prior to screening
HDL-C < 50 mg/dL for men and < 55 mg/dL for women
Body Mass Index (BMI) of approximately 18 to 35 kg/m^2; and a total body weight >= 50 kg (110 lbs) and <= 110 kg (approximately 242 lbs)

Exclusion Criteria:

Myocardial infarction, stroke, or coronary intervention/revascularization procedure within 6 months prior to dosing.
Chronic heart failure (> New York Heart Association (NYHA) Functional Classification II).
Ventricular tachyarrhythmias.
Uncontrolled Type 2 (HbA1c > 8.5%) or Type 1 diabetes mellitus.
History of febrile illness within 5 days prior to dosing.
History of regular alcohol consumption exceeding 10 drinks per week.
12-lead ECG demonstrating QTc > 500 msec at screening.
Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of trial results and, in the judgment of the investigator, would make the subject inappropriate for entry into this trial.
No Results Posted